JP2014521605A - Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対してワクチン接種するための方法および組成物 - Google Patents

Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対してワクチン接種するための方法および組成物 Download PDF

Info

Publication number
JP2014521605A
JP2014521605A JP2014521610A JP2014521610A JP2014521605A JP 2014521605 A JP2014521605 A JP 2014521605A JP 2014521610 A JP2014521610 A JP 2014521610A JP 2014521610 A JP2014521610 A JP 2014521610A JP 2014521605 A JP2014521605 A JP 2014521605A
Authority
JP
Japan
Prior art keywords
vaccine
staphylococcus aureus
als3p
use according
candida
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014521610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521605A5 (enExample
Inventor
マイケル アール． イーマン，
ジョン イー． ジュニア エドワーズ，
スコット ジー． フィラー，
アシュラフ エス． イブラヒム，
ユエ フー，
ジョン ピー． ジュニア ヘネシー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2014521605A publication Critical patent/JP2014521605A/ja
Publication of JP2014521605A5 publication Critical patent/JP2014521605A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014521610A 2011-07-22 2012-07-20 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対してワクチン接種するための方法および組成物 Pending JP2014521605A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161510896P 2011-07-22 2011-07-22
US61/510,896 2011-07-22
PCT/US2012/000328 WO2013015831A1 (en) 2011-07-22 2012-07-20 Methods and compositions for vaccinating against staphylococcus aureus

Publications (2)

Publication Number Publication Date
JP2014521605A true JP2014521605A (ja) 2014-08-28
JP2014521605A5 JP2014521605A5 (enExample) 2015-08-27

Family

ID=47601425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521610A Pending JP2014521605A (ja) 2011-07-22 2012-07-20 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対してワクチン接種するための方法および組成物

Country Status (12)

Country Link
US (1) US10653757B2 (enExample)
EP (1) EP2734229B1 (enExample)
JP (1) JP2014521605A (enExample)
CN (1) CN103998056B (enExample)
AU (1) AU2012287513A1 (enExample)
BR (1) BR112014001409A2 (enExample)
CA (1) CA2842626A1 (enExample)
EA (1) EA035513B1 (enExample)
ES (1) ES2716800T3 (enExample)
GE (1) GEP201706766B (enExample)
UA (1) UA114286C2 (enExample)
WO (1) WO2013015831A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507759A (ja) * 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
WO2014153241A1 (en) 2013-03-14 2014-09-25 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
HK1220389A1 (zh) * 2013-03-14 2017-05-05 Wang Rongfu 调控调节性t细胞功能的方法和组合物
BR112015022963A8 (pt) * 2013-03-15 2018-01-16 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct composições e métodos para tratar patógenos fúngicos e bacterianos.
CN105713096B (zh) * 2016-03-29 2019-01-01 黑龙江八一农垦大学 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
JP7439371B2 (ja) 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー－ ユーシーエルエー メディカル センター Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
KR20260052081A (ko) * 2023-08-09 2026-04-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 단백질
WO2025240443A1 (en) * 2024-05-14 2025-11-20 University Of Rochester Candida for use in prevention or mitigation of cutaneous viral infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124134A1 (en) * 1999-11-19 2003-07-03 Harbor-Ucla Research And Education Institute Pharmaceutical compositions and methods to vaccinate against candidiasis
JP2007512312A (ja) * 2003-11-21 2007-05-17 ファイザー・プロダクツ・インク ワクチンアジュバントとしての抗生物質の使用
JP2009524601A (ja) * 2006-01-06 2009-07-02 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
JPH09500013A (ja) 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6500438B2 (en) 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
CA2486618C (en) 2002-05-21 2013-04-09 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and uses thereof
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
WO2007123850A2 (en) 2006-04-17 2007-11-01 Schering-Plough Ltd. Recombinant attenuated clostridium organisms and vaccine
WO2008147847A1 (en) 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
EP2296698A1 (en) 2008-05-29 2011-03-23 Intervet International BV Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
ES2606555T3 (es) 2009-07-03 2017-03-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center HYR1 como objetivo para la inmunización activa y pasiva contra Candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124134A1 (en) * 1999-11-19 2003-07-03 Harbor-Ucla Research And Education Institute Pharmaceutical compositions and methods to vaccinate against candidiasis
JP2007512312A (ja) * 2003-11-21 2007-05-17 ファイザー・プロダクツ・インク ワクチンアジュバントとしての抗生物質の使用
JP2009524601A (ja) * 2006-01-06 2009-07-02 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JP2012530786A (ja) * 2009-06-22 2012-12-06 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507759A (ja) * 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット

Also Published As

Publication number Publication date
CA2842626A1 (en) 2013-01-31
US10653757B2 (en) 2020-05-19
US20150273031A1 (en) 2015-10-01
EP2734229A1 (en) 2014-05-28
EA201391200A1 (ru) 2014-05-30
BR112014001409A2 (pt) 2017-07-11
UA114286C2 (uk) 2017-05-25
AU2012287513A1 (en) 2014-03-13
EA035513B1 (ru) 2020-06-29
CN103998056B (zh) 2017-09-12
EP2734229B1 (en) 2019-01-02
CN103998056A (zh) 2014-08-20
AU2012287513A8 (en) 2014-06-19
GEP201706766B (en) 2017-10-25
WO2013015831A1 (en) 2013-01-31
EP2734229A4 (en) 2015-01-21
ES2716800T3 (es) 2019-06-17

Similar Documents

Publication Publication Date Title
US10653757B2 (en) Methods and compositions for vaccinating against Staphylococcus aureus
JP6167130B2 (ja) Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
Portuondo et al. A cell wall protein-based vaccine candidate induce protective immune response against Sporothrix schenckii infection
Wang et al. Vaccines in the treatment of invasive candidiasis
JP6655549B2 (ja) 免疫応答を誘導するための新規方法
EP2968497B1 (en) Compositions and methods for treating fungal and bacterial pathogens
JP2017513860A (ja) 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
JP2019507759A (ja) 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット
US20150191514A1 (en) Hyr1-derived compositions and methods of treatment using same
Luo et al. mRNA-based platform for preventing and treating Staphylococcus aureus by targeted staphylococcal enterotoxin B
JP2017513849A (ja) Ａ群レンサ球菌ワクチン
CN121015856A (zh) 一种呼吸道合胞病毒疫苗组合物
JP2020028219A (ja) マラリアワクチン
Khosravani Pour et al. Enhanced immunogenicity of Staphylococcus aureus IsdE vaccine with SeNPs and BCG adjuvants in mice
US20160030533A1 (en) Compositions and methods of treating fungal and bacterial pathogens
Khodadad et al. A comprehensive review of neurotropic fungal infections: clinical manifestations and vaccines
Hassanzadeh Enhanced immunogenicity of Staphylococcus aureusIsdE vaccine with SeNPs and BCG adjuvants in mice
TWI839105B (zh) 用於治療和預防冠狀病毒感染的藥物組合物
Wu et al. Coupling of the Hla-IsdB fusion antigen to mi3 nanoparticles enhances dendritic cell activation and protects against Staphylococcus aureus skin infection
Gong et al. OPEN ACCESS EDITED BY
Smith et al. Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160921